Developing Targeting Techniques for the Advancement of In Vivo Gene Therapies- [electronic resource]
Developing Targeting Techniques for the Advancement of In Vivo Gene Therapies- [electronic resource]
- 자료유형
- 학위논문파일 국외
- 최종처리일시
- 20240214101219
- ISBN
- 9798379907877
- DDC
- 610
- 서명/저자
- Developing Targeting Techniques for the Advancement of In Vivo Gene Therapies - [electronic resource]
- 발행사항
- [S.l.]: : University of Washington., 2023
- 발행사항
- Ann Arbor : : ProQuest Dissertations & Theses,, 2023
- 형태사항
- 1 online resource(79 p.)
- 주기사항
- Source: Dissertations Abstracts International, Volume: 85-01, Section: B.
- 주기사항
- Advisor: Kiem, Hans-Peter.
- 학위논문주기
- Thesis (Ph.D.)--University of Washington, 2023.
- 사용제한주기
- This item must not be sold to any third party vendors.
- 초록/해제
- 요약Hematopoietic Stem Cell (HSC) gene therapy is a promising route to curing patients with a variety of hematologic diseases and disorders. HSC gene therapy is currently performed ex vivo and requires rare cleanroom infrastructure, which is a significant obstacle to patients in resource impoverished areas. Application of gene therapy agents directly in the patient (in vivo) would overcome this bottleneck. We have previously identified the CD34+CD90+ subset to be exclusively responsible for short- and long-term engraftment. However, purification and enrichment of this subset is laborious and expensive. HSC-specific delivery agents for the direct modification of rare HSCs are currently lacking. Here, we developed novel targeted viral vectors to specifically transduce CD90-expressing HSCs. Anti-CD90 single chain variable fragments (scFvs) were engineered onto measles- and VSVG-pseudotyped lentiviral vectors that were knocked out for native targeting. We further developed a custom hydrodynamic titration methodology to assess the loading of surface-engineered capsids, measure antigen recognition of the scFv, and predict the performance on cells. Engineered vectors formed with minimal impairment in the functional titer maintained their ability to fuse with the target cells and showed highly specific recognition of CD90 on cells ex vivo. Most importantly, targeted vectors selectively transduced human HSCs with secondary colony-forming potential. However, agents recognizing only a single marker on target cells are often insufficient due to epitope sharing in between on- and off-target tissues. The Baker Lab previously designed a system of protein switches known as Co-LOCKR, which enable the specific recognition of two antigens simultaneously. Co-LOCKR targeted CAR T cells highly specifically killed tumor cells in vitro with virtually no off-target effects. Therefore, we further designed and evaluated Co-LOCKR-targeted viral vectors for ex vivo as well as in vivo applicability and comprehensively evaluated the on-target specificity in a murine tumor model. Together this work lays a foundation and provides a robust toolset for the exploration of in vivo gene therapies.
- 일반주제명
- Biomedical engineering.
- 일반주제명
- Cellular biology.
- 일반주제명
- Genetics.
- 키워드
- Cell therapy
- 키워드
- Gene therapy
- 기타저자
- University of Washington Molecular Medicine and Mechanisms of Disease
- 기본자료저록
- Dissertations Abstracts International. 85-01B.
- 기본자료저록
- Dissertation Abstract International
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.